MiddleBrook Pharmaceuticals Announces Board of Directors Resignations
2010年3月24日 - 5:45AM
ビジネスワイヤ(英語)
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) today announced
that James H. Cavanaugh, Ph.D., Martin A. Vogelbaum and Harold R.
Werner have resigned from the Company’s Board of Directors
effective immediately.
“We thank Jim, Martin and Hal for their contributions to
MiddleBrook as Board members,” said Dave Becker, acting president
and chief executive officer of MiddleBrook.
About MiddleBrook
Pharmaceuticals
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) currently
markets MOXATAG, the first and only FDA-approved once-daily
amoxicillin, and KEFLEX (cephalexin, USP), the immediate-release
brand of cephalexin. MiddleBrook’s proprietary delivery technology,
PULSYS, enables the pulsatile delivery, or delivery in rapid
bursts, of certain drugs. For more information about MiddleBrook,
please visit www.middlebrookpharma.com.
MiddleBrook, MiddleBrook Pharmaceuticals (stylized), MiddleBrook
Pharmaceuticals, Inc., are MiddleBrook’s trademarks and have been
registered in the U.S. Patent and Trademark Office or are the
subject of pending U.S. trademarks applications. References to
“we,” ‘‘us,” “our,” ‘‘MiddleBrook,” or the “Company,” refer to
MiddleBrook Pharmaceuticals, Inc., and its subsidiaries.
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
過去 株価チャート
から 4 2024 まで 5 2024
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
過去 株価チャート
から 5 2023 まで 5 2024
Real-Time news about Middlebrook Pharmaceuticals (MM) (ナスダック市場): 0 recent articles
その他のMiddleBrook Pharmaceuticals, Inc.ニュース記事